Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Anti-HPV16 E2 protein T-cell responses and viral control in women with usual vulvar intraepithelial neoplasia and their healthy partners.

Jacobelli S, Sanaa F, Moyal-Barracco M, Pelisse M, Berville S, Villefroy P, North MO, Figueiredo S, Charmeteau B, Clerici T, Plantier F, Arnold F, Touzé A, Dupin N, Avril MF, Guillet JG, Cheynier R, Bourgault-Villada I.

PLoS One. 2012;7(5):e36651. doi: 10.1371/journal.pone.0036651. Epub 2012 May 9.

2.

Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6.

de Jong A, van Poelgeest MI, van der Hulst JM, Drijfhout JW, Fleuren GJ, Melief CJ, Kenter G, Offringa R, van der Burg SH.

Cancer Res. 2004 Aug 1;64(15):5449-55.

3.

Epitope specificity and longevity of a vaccine-induced human T cell response against HPV18.

Smith KL, Tristram A, Gallagher KM, Fiander AN, Man S.

Int Immunol. 2005 Feb;17(2):167-76. Epub 2004 Dec 27.

PMID:
15623547
4.

Human papillomavirus 16-specific T cell responses in classic HPV-related vulvar intra-epithelial neoplasia. Determination of strongly immunogenic regions from E6 and E7 proteins.

Bourgault Villada I, Moyal Barracco M, Berville S, Bafounta ML, Longvert C, Prémel V, Villefroy P, Jullian E, Clerici T, Paniel B, Maillère B, Choppin J, Guillet JG.

Clin Exp Immunol. 2010 Jan;159(1):45-56. doi: 10.1111/j.1365-2249.2009.04006.x. Epub 2009 Jul 30.

5.

Spontaneous regression of grade 3 vulvar intraepithelial neoplasia associated with human papillomavirus-16-specific CD4(+) and CD8(+) T-cell responses.

Bourgault Villada I, Moyal Barracco M, Ziol M, Chaboissier A, Barget N, Berville S, Paniel B, Jullian E, Clerici T, Maillère B, Guillet JG.

Cancer Res. 2004 Dec 1;64(23):8761-6.

6.

Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses.

Welters MJ, Kenter GG, de Vos van Steenwijk PJ, Löwik MJ, Berends-van der Meer DM, Essahsah F, Stynenbosch LF, Vloon AP, Ramwadhdoebe TH, Piersma SJ, van der Hulst JM, Valentijn AR, Fathers LM, Drijfhout JW, Franken KL, Oostendorp J, Fleuren GJ, Melief CJ, van der Burg SH.

Proc Natl Acad Sci U S A. 2010 Jun 29;107(26):11895-9. doi: 10.1073/pnas.1006500107. Epub 2010 Jun 14.

7.

Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins.

Davidson EJ, Boswell CM, Sehr P, Pawlita M, Tomlinson AE, McVey RJ, Dobson J, Roberts JS, Hickling J, Kitchener HC, Stern PL.

Cancer Res. 2003 Sep 15;63(18):6032-41.

8.

Cell mediated immunity against HPV16 E2, E6 and E7 peptides in women with incident CIN and in constantly HPV-negative women followed-up for 10-years.

Paaso A, Koskimaa HM, Welters MJ, Grénman S, Syrjänen K, van der Burg SH, Syrjänen S.

J Transl Med. 2015 May 20;13:163. doi: 10.1186/s12967-015-0498-9.

9.

Detection of human papillomavirus (HPV) 16-specific CD4+ T-cell immunity in patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment.

van Poelgeest MI, van Seters M, van Beurden M, Kwappenberg KM, Heijmans-Antonissen C, Drijfhout JW, Melief CJ, Kenter GG, Helmerhorst TJ, Offringa R, van der Burg SH.

Clin Cancer Res. 2005 Jul 15;11(14):5273-80.

10.

Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia.

Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, Essahsah F, Fathers LM, Offringa R, Drijfhout JW, Wafelman AR, Oostendorp J, Fleuren GJ, van der Burg SH, Melief CJ.

N Engl J Med. 2009 Nov 5;361(19):1838-47. doi: 10.1056/NEJMoa0810097.

11.

Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.

Welters MJ, Kenter GG, Piersma SJ, Vloon AP, Löwik MJ, Berends-van der Meer DM, Drijfhout JW, Valentijn AR, Wafelman AR, Oostendorp J, Fleuren GJ, Offringa R, Melief CJ, van der Burg SH.

Clin Cancer Res. 2008 Jan 1;14(1):178-87. doi: 10.1158/1078-0432.CCR-07-1880.

12.

Human papillomavirus type 16 E2- and L1-specific serological and T-cell responses in women with vulval intraepithelial neoplasia.

Davidson EJ, Sehr P, Faulkner RL, Parish JL, Gaston K, Moore RA, Pawlita M, Kitchener HC, Stern PL.

J Gen Virol. 2003 Aug;84(Pt 8):2089-97.

PMID:
12867639
13.

T-cell response to human papillomavirus type 52 L1, E6, and E7 peptides in women with transient infection, cervical intraepithelial neoplasia, and invasive cancer.

Chan PK, Liu SJ, Cheung JL, Cheung TH, Yeo W, Chong P, Man S.

J Med Virol. 2011 Jun;83(6):1023-30. doi: 10.1002/jmv.21889.

PMID:
21503915
14.

Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects.

de Jong A, van der Burg SH, Kwappenberg KM, van der Hulst JM, Franken KL, Geluk A, van Meijgaarden KE, Drijfhout JW, Kenter G, Vermeij P, Melief CJ, Offringa R.

Cancer Res. 2002 Jan 15;62(2):472-9.

15.

Distinct regulation and impact of type 1 T-cell immunity against HPV16 L1, E2 and E6 antigens during HPV16-induced cervical infection and neoplasia.

van Poelgeest MI, Nijhuis ER, Kwappenberg KM, Hamming IE, Wouter Drijfhout J, Fleuren GJ, van der Zee AG, Melief CJ, Kenter GG, Nijman HW, Offringa R, van der Burg SH.

Int J Cancer. 2006 Feb 1;118(3):675-83.

16.

Comparison of cervical and blood T-cell responses to human papillomavirus-16 in women with human papillomavirus-associated cervical intraepithelial neoplasia.

Passmore JA, Milner M, Denny L, Sampson C, Marais DJ, Allan B, Gumbi PP, Hitzeroth II, Rybicki EP, Williamson AL.

Immunology. 2006 Dec;119(4):507-14. Epub 2006 Oct 9.

17.

Surgery followed by persistence of high-grade squamous intraepithelial lesions is associated with the induction of a dysfunctional HPV16-specific T-cell response.

de Vos van Steenwijk PJ, Piersma SJ, Welters MJ, van der Hulst JM, Fleuren G, Hellebrekers BW, Kenter GG, van der Burg SH.

Clin Cancer Res. 2008 Nov 15;14(22):7188-95. doi: 10.1158/1078-0432.CCR-08-0994.

18.

Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia.

Baldwin PJ, van der Burg SH, Boswell CM, Offringa R, Hickling JK, Dobson J, Roberts JS, Latimer JA, Moseley RP, Coleman N, Stanley MA, Sterling JC.

Clin Cancer Res. 2003 Nov 1;9(14):5205-13.

19.

Disturbed patterns of immunocompetent cells in usual-type vulvar intraepithelial neoplasia.

van Seters M, Beckmann I, Heijmans-Antonissen C, van Beurden M, Ewing PC, Zijlstra FJ, Helmerhorst TJ, KleinJan A.

Cancer Res. 2008 Aug 15;68(16):6617-22. doi: 10.1158/0008-5472.CAN-08-0327.

20.

Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination.

Smyth LJ, Van Poelgeest MI, Davidson EJ, Kwappenberg KM, Burt D, Sehr P, Pawlita M, Man S, Hickling JK, Fiander AN, Tristram A, Kitchener HC, Offringa R, Stern PL, Van Der Burg SH.

Clin Cancer Res. 2004 May 1;10(9):2954-61.

Supplemental Content

Support Center